Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03373461
Recruitment Status : Recruiting
First Posted : December 14, 2017
Last Update Posted : May 24, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Efficacy and safety of LNP023 in IgAN patients

Condition or disease Intervention/treatment Phase
IgA Nephropathy Drug: LNP023 Drug: Placebo Phase 2

Detailed Description:
The purpose of this Phase IIa/IIb dose ranging study is to generate human data in the intended patient population with IgAN to establish clinical proof-of-concept and to evaluate dose responses to support dose selection for subsequent clinical development of LNP023 for IgAN and potentially other indications

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The primary variable is the change from baseline of log transformed UPCR derived from the 24h urine collections at baseline and day 90.

An interim analysis will be performed once the last patient has completed treatment in Part 1. The intention of this analysis is to provide preliminary evidence of dose-response relationship for proteinuria, to determine the sample size for Part 2, and to determine the treatment arms to be studied in Part 2.

Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Actual Study Start Date : February 7, 2018
Estimated Primary Completion Date : April 12, 2021
Estimated Study Completion Date : July 12, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo to LNP023
Drug: Placebo
Placebo to LPN023 b.i.d

Experimental: LNP023 dose 1
Dose 1 of LNP023
Drug: LNP023
LNP023 b.i.d. Dose 1, Dose 2 and Dose 3

Experimental: LNP023 dose 2
Dose 2 of LNP023
Drug: LNP023
LNP023 b.i.d. Dose 1, Dose 2 and Dose 3

Experimental: LNP023 dose 3
Dose 3 of LNP023
Drug: LNP023
LNP023 b.i.d. Dose 1, Dose 2 and Dose 3




Primary Outcome Measures :
  1. change from baseline of urine protein to creatinine concentration [ Time Frame: Baseline and Day 90 ]
    baseline of urine protein to creatinine concentration ratio (UPCR based on 24h urine collection) at 90 days


Secondary Outcome Measures :
  1. The effect of LNP023 on renal function - Estimated Glomerular Filtration Rate eGFR [ Time Frame: Baseline, Day 1, 8, 15, 30, 90, 120 ]
    eGFR; estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)

  2. The effect of LNP023 on renal function - Serum creatinine [ Time Frame: Baseline, Day 1, 8, 15, 30, 90, 120 ]
    Serum creatinine

  3. The effect of LNP023 on renal function - Hematuria [ Time Frame: Baseline, Day 1, 8, 15, 30, 60, 90, 120, 180 ]
    Hematuria (number of erythrocytes/high-power-field (hpf) measured through microscopic examination)

  4. The effect of LNP023 on renal function - 24h-UP, 24h-UA, UACR (urine albumin to creatinine concentration ratio) [ Time Frame: Baseline, Day 1, 30, 60, 90, 120, 180 ]
    24h-UP, 24h-UA, UACR (urine albumin to creatinine concentration ratio)

  5. Plasma Pharmacokinetics (PK) of LNP023: Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: Baseline, Day 1, 8, 15, 30, 60, 90 ]

    AUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval

    AUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis.


  6. Observed Maximum Concentration (Cmax) after Drug Administration [ Time Frame: Baseline, Day 1, 8, 15, 30, 60, 90 ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.

  7. The effect of LNP023 on alternative complement pathway [ Time Frame: Baseline, Day 1, 8, 15, 30, 60, 90 ]
    Bb and sC5b-9

  8. To estimate the lowest dose that provides maximal reduction of proteinuria [ Time Frame: Baseline, Day 1, 8, 15, 30, 60, 90 ]
    Ratio to baseline of UPCR urinary prt at the lowest dose that provide

  9. Time to Reach the Maximum Plasma Concentration (Tmax) [ Time Frame: Baseline, Day 1, 8, 15, 30, 60, 90 ]
    Blood samples for pharmacokinetic (PK) evaluation were drawn pre-dose and at 3, 6, and 12 hours on Day 1; at 0 and 12 hours on Day 2; and on Days 3, 4, 6, 8, 10, 14, 18, 22, and 26 following administration of iloperidone. PK parameters were calculated from plasma concentration-time data using non-compartmental methods.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female and male patients above 18 years of age with a biopsy-verified IgA nephropathy and where the biopsy was performed within the prior three years.
  • Patients must weigh at least 35 kg to participate in the study, and must have a body mass index (BMI) within the range of 15 - 38 kg/m2. BMI = Body weight (kg) / [Height (m)]2
  • Measured Glomerular Filtration Rate (GFR) or estimated GFR (using the CKD-EPI formula) ≥30 mL/min per 1.73 m2
  • Urine protein ≥1 g/24hr at screening and ≥0.75 g / 24h after the run- in period
  • Vaccination against Neisseria meningitidis types A, C, Y and W-135 is required at least 30 days prior to first dosing with LNP023. Vaccination against N. meningitidis type B, S. pneumoniae and H. influenzae should be conducted if available and acceptable by local regulations, at least 30 days prior to first dosing with LNP023
  • All patients must have been on supportive care including a maximally tolerated dose of ACEi or ARB therapy for the individual, antihypertensive therapy or diuretics for at least 90 days before dosing

Exclusion criteria

  1. Presence of crescent formation in ≥50% of glomeruli assessed on renal biopsy
  2. Patients previously treated with immunosuppressive agents such as cyclophosphamide or mycophenolate mofetil (MMF), or cyclosporine, systemic corticosteroids exposure within 90 days prior to start of LNP023/Placebo dosing
  3. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations
  4. All transplanted patients (any organ, including bone marrow)
  5. History of immunodeficiency diseases, or a positive HIV (ELISA and Western blot) test result.

    Chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV). A positive HBV surface antigen (HBsAg) test, or if standard local practice, a positive HBV core antigen test, excludes a patient. Patients with a positive HCV antibody test should have HCV RNA levels measured. Subjects with positive (detectable) HCV RNA should be excluded

  6. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study. The Investigator should make this determination in consideration of the subject's medical history and/or clinical or laboratory evidence of any of the following:

    • A history of invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus
    • Splenectomy
    • Inflammatory bowel disease, peptic ulcers, severe gastrointestinal disorder including rectal bleeding;
    • Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
    • Pancreatic injury or pancreatitis;
    • Liver disease or liver injury as indicated by abnormal liver function tests. ALT (SGPT), AST (SGOT), GGT, alkaline phosphatase and serum bilirubin will be tested.
    • Any single parameter of ALT, AST, GGT, alkaline phosphatase or serum bilirubin must not exceed 3 x upper limit of normal (ULN)
    • PT/INR must be within the reference range of normal individuals
    • Evidence of urinary obstruction or difficulty in voiding any urinary tract disorder other than IgNA that is associated with hematuria at screening and before dosing; [If necessary, laboratory testing may be repeated on one occasion (as soon as possible) prior to randomization, to rule out any laboratory error]
  7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  8. A history of clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening or baseline:

    • PR > 200 msec
    • QRS complex > 120 msec
    • QTcF > 450 msec (males)
    • QTcF > 460 msec (females)
    • History of familial long QT syndrome or known family history of Torsades de Pointes
    • Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of the study
  9. History of severe allergic reactions as per Investigator decision
  10. Plasma donation (> 200mL) within 30 days prior to first dosing.
  11. Donation or loss of 400 mL or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation
  12. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug. Highly effective contraception methods include:

    • Total abstinence from heterosexual intercourse (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    • Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject.
    • Use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure <1%), for example hormone vaginal ring or transdermal hormone contraception In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug.

    If local regulations deviate from the contraception methods listed above and require more extensive measures to prevent pregnancy, local regulations apply and will be described in the ICF.

    Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

  13. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
  14. History of any porphyria metabolic disorder
  15. History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during screening and baseline.
  16. History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03373461


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals +41613241111

  Show 28 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03373461     History of Changes
Other Study ID Numbers: CLNP023X2203
2017-000891-27 ( EudraCT Number )
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: May 24, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
glomerunephritis, complement driven, chronic kidney disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Glomerulonephritis, IGA
Urologic Diseases
Glomerulonephritis
Nephritis
Autoimmune Diseases
Immune System Diseases